Key result
Healthy lifestyle program cuts weekly cardiometabolic medication costs nearly in half at 24 months.
Why the study?
Non-communicable diseases contribute immensely to health care costs through medication use, and the effect of the Healthy Lifestyle Community Program on medication use and costs for diabetes, hypertension, and dyslipidemia required evaluation.
Answers are grounded in this paper and cite their sources.
Background: Establishing a healthy lifestyle has a great potential to reduce the prevalence of non-communicable diseases (NCDs) and their risk factors. NCDs contribute immensely to the economic costs of the health care system arising from therapy, medication use, and productivity loss. Aim: The aim of this study was to evaluate the effect of the Healthy Lifestyle Community Program (cohort 2; HLCP-2) on medication use and consequently on medication costs for selected NCDs (diabetes, hypertension, and dyslipidemia). Methods: Data stem from a 24-month non-randomised, controlled intervention trial aiming to improve risk factors for NCDs. Participants completed questionnaires at six measurement time points assessing medication use, from which costs were calculated. The following medication groups were included in the analysis as NCD medication: glucose-lowering medications (GLM), antihypertensive drugs (AHD) and lipid-lowering drugs (LLD). Statistical tests for inter- and intra-group comparison and multiple regression analysis were performed. Results: In total, 118 participants (intervention group [IG]: n = 79; control group [CG]: n = 39) were considered. Compared to baseline medication use decreased slightly in the IG and increased in the CG. Costs for NCD medication were significantly lower in the IG than in the CG after 6 ( p = 0.004), 12 ( p = 0.040), 18 ( p = 0.003) and 24 months ( p = 0.008). After multiple regression analysis and adjusting for confounders, change of costs differed significantly between the groups in all final models. Conclusion: The HLCP-2 was able to moderately prevent an increase of medication use and thus reduce costs for medication to treat NCDs with the greatest impact on AHD. Trial registration German Clinical Trials Register DRKS ( www.drks.de ; reference: DRKS00018775).
No takes yet. Share an insight, caveat, or question.
Kranz et al. (2023) studied Non-communicable diseases (diabetes, hypertension, and dyslipidemia) (n=118). Healthy Lifestyle Community Program (cohort 2; HLCP-2) vs. No intervention (control group informed of personal health check results) was evaluated on Weekly medication costs (in €) for non-communicable diseases (glucose-lowering, antihypertensive, and lipid-lowering drugs) at 24 months (Beta 1.749 (adjusted difference in cost change at 24 months), p=0.008). The Healthy Lifestyle Community Program resulted in significantly lower weekly NCD medication costs at 24 months compared to control (3.75 € vs 6.66 €; p = 0.008).
Synapse has enriched 10 related papers. Consider them for comparative context: